Voyager Therapeutics (VYGR) to Release Earnings on Tuesday

Voyager Therapeutics (NASDAQ:VYGR) is projected to announce its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect the company to announce earnings of ($0.54) per share and revenue of $10.4920 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.

Voyager Therapeutics Trading Down 0.8%

NASDAQ:VYGR opened at $3.90 on Friday. The stock has a market cap of $216.84 million, a P/E ratio of -1.81 and a beta of 1.32. The stock has a 50 day simple moving average of $3.85 and a 200 day simple moving average of $4.13. Voyager Therapeutics has a 1-year low of $2.64 and a 1-year high of $5.55.

Wall Street Analyst Weigh In

Several research firms have weighed in on VYGR. Wedbush reiterated an “outperform” rating and set a $8.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Wall Street Zen cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Finally, HC Wainwright decreased their price target on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, November 12th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Voyager Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $13.75.

Insider Buying and Selling

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 14,197 shares of Voyager Therapeutics stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $3.79, for a total value of $53,806.63. Following the completion of the transaction, the chief executive officer directly owned 484,060 shares of the company’s stock, valued at $1,834,587.40. The trade was a 2.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 49,783 shares of company stock worth $188,694. 6.39% of the stock is owned by company insiders.

Institutional Trading of Voyager Therapeutics

Several large investors have recently modified their holdings of VYGR. Sphera Funds Management LTD. raised its stake in Voyager Therapeutics by 70.1% in the fourth quarter. Sphera Funds Management LTD. now owns 339,761 shares of the company’s stock valued at $1,335,000 after purchasing an additional 140,000 shares in the last quarter. Two Sigma Investments LP bought a new position in Voyager Therapeutics in the 3rd quarter valued at about $657,000. Barclays PLC increased its holdings in Voyager Therapeutics by 2.5% in the 4th quarter. Barclays PLC now owns 162,112 shares of the company’s stock valued at $637,000 after buying an additional 4,003 shares during the period. Wells Fargo & Company MN raised its position in shares of Voyager Therapeutics by 26.7% in the 4th quarter. Wells Fargo & Company MN now owns 132,663 shares of the company’s stock valued at $521,000 after buying an additional 27,964 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Voyager Therapeutics by 28.2% during the 4th quarter. Invesco Ltd. now owns 116,000 shares of the company’s stock worth $456,000 after acquiring an additional 25,522 shares during the period. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.